AI
NRXP icon

AdvisorShares Investments’s NRX Pharmaceuticals NRXP Stock Holding History

AdvisorShares Investments’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Buy
659,018
+238,551
+57% +$788K 0.33% 47
2026
Q1 		$896K Buy
420,467
+92,463
+28% +$187K 0.16% 90
2025
Q4 		$889K Sell
328,004
-14,132
-4% -$37.9K 0.15% 83
2025
Q3 		$1.13M Buy
342,136
+78,339
+30% +$224K 0.18% 62
2025
Q2 		$860K Sell
263,797
-23,000
-8% -$57.6K 0.16% 76
2025
Q1 		$556K Sell
286,797
-23,517
-8% -$66.3K 0.11% 93
2024
Q4 		$683K Buy
310,314
+180,229
+139% +$242K 0.13% 69
2024
Q3 		$220K Buy
130,085
+22,000
+20% +$44.3K 0.04% 212
2024
Q2 		$279K Buy
108,085
+46,606
+76% +$166K 0.05% 204
2024
Q1 		$290K Sell
61,479
-2,784
-4% -$12.8K 0.05% 215
2023
Q4 		$296K Buy
+64,263
New +$212K 0.07% 208

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AdvisorShares Investments's NRXP Position: Q2 2026 in Review

AdvisorShares Investments increased its NRX Pharmaceuticals (NRXP) stake by 57% in Q2 2026, buying an estimated $788K and bringing the position to 659,018 shares worth $2.7M. The position accounts for 0.33% of the portfolio, ranked #47.

AdvisorShares Investments first reported a position in NRXP in Q4 2023 and has held it in 11 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • AdvisorShares Investments held 659,018 shares of NRX Pharmaceuticals worth $2.7M as of Q2 2026.
  • AdvisorShares Investments bought 238,551 NRX Pharmaceuticals shares in Q2 2026, an estimated $788K.
  • NRX Pharmaceuticals made up 0.33% of AdvisorShares Investments's portfolio in Q2 2026, its #47 holding.
  • AdvisorShares Investments first reported a position in NRX Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.